Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analytical Models to Optimize Tacrolimus Dosing in Solid Organ Transplantation: A Systematic Review.

Pharmaceutics·2026
Same author

Expression Analysis of the orphan receptors GPR161, GPR132, GPR20, and GPR139 in patients with cervicitis and low-grade, and high-grade squamous intraepithelial lesions.

Genetics and molecular biology·2026
Same author

Isoindolines and Isoindoline-1,3-diones as Nonpeptide ACE Inhibitors: An <i>In Silico</i> and <i>In Vitro</i> Modeling Approach.

ACS medicinal chemistry letters·2026
Same author

Low intensity vibration with zoledronate reduces musculoskeletal weakness and adiposity in estrogen deprived female mice.

Nature communications·2026
Same author

Presenilin L166P Mutation, a Model of Familial Alzheimer's Disease, Leads to Early Onset Bone Loss.

Comprehensive Physiology·2026
Same author

Investigating the Impact of Screen-Sharing Visual Aids during Genomic Results Disclosure via Telehealth in Diverse Families in the TeleKidSeq Pilot Study.

Public health genomics·2025

Related Experiment Video

Updated: Jun 24, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Familial hypertrophic cardiomyopathy: basic concepts and future molecular diagnostics.

Jessica E Rodríguez1, Christopher R McCudden, Monte S Willis

  • 1Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599-7525, USA.

Clinical Biochemistry
|March 26, 2009
PubMed
Summary

Familial hypertrophic cardiomyopathies (FHC) are common genetic heart diseases. New high-throughput sequencing methods offer improved diagnosis for FHC, a condition often unnoticed until sudden cardiac death occurs.

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

Related Experiment Videos

Last Updated: Jun 24, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

Area of Science:

  • Cardiology
  • Genetics
  • Molecular Biology

Background:

  • Familial hypertrophic cardiomyopathies (FHC) are the most prevalent genetic heart diseases in the U.S., affecting approximately 1 in 500 individuals.
  • Characterized by increased cardiac wall thickness, FHC is an autosomal dominant condition often presenting asymptomatically, masking its potentially fatal consequences, including sudden cardiac death in young individuals and adults.
  • The genetic heterogeneity of FHC, primarily involving sarcomere proteins, presents significant challenges for accurate and timely diagnosis using current methods.

Purpose of the Study:

  • To review the pathophysiology of familial hypertrophic cardiomyopathies.
  • To discuss the rationale and importance of genetic testing for FHC.
  • To evaluate the limitations and advantages of current and emerging diagnostic technologies for FHC.

Main Methods:

  • Review of current literature on FHC genetics, pathophysiology, and diagnostics.
  • Discussion of array-based resequencing using high-throughput microarray technology for mutation identification.
  • Exploration of next-generation sequencing methodologies for enhanced FHC diagnosis.

Main Results:

  • FHC diagnosis is complicated by genetic heterogeneity, impacting the effectiveness of current diagnostic tools.
  • Array-based resequencing represents a novel high-throughput approach for identifying FHC-associated mutations.
  • Next-generation sequencing holds promise for improving the accuracy and efficiency of FHC diagnosis.

Conclusions:

  • Accurate and rapid diagnosis of FHC is crucial for early intervention and reducing mortality rates.
  • Advanced molecular technologies, including array-based resequencing and next-generation sequencing, are poised to revolutionize FHC diagnostics.
  • Further research and clinical implementation of these advanced methods are essential for better management of FHC patients.